PIXUVRI (pixantrone), anthracycline and related

• Since 2012, PIXUVRI has had conditional Marketing Authorisation as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL).
• The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.
• No new study is available since the previous assessment. Its therapeutic benefit therefore remains to be confirmed considering:

       - the non-optimal level of demonstration of efficacy in a single study,

       - the marked safety profile, especially for a haematological (neutropenia) and cardiac toxicity, 

       - the absence of data on quality of life, in particular at this advanced stage of the disease.

•  The role of this cytotoxic agent related to anthracyclines in monotherapy is restricted to the 3^rd or 4^th line of the therapeutic strategy.